Pharma's China subsidiaries undergo massive changes
By Kim, Jin-Gu | translator Eo, Yun-Ho
24.09.11 05:08:59
가나다라
0
GC Biopharma is selling its China subsidiary at KRW 350 billion…Il-Yang Pharm has decided to liquidate TongHua IL-YANG
Beijing Hanmi Pharm affected by management dispute…China subsidiaries of CKD·Kwang Dong·Pharm Huons face poor sales performance
Companies seek to establish business operations in nations other than China…establishing new local subsidiaries in the U.S.·Europe·Vietnam
▲(From left) Beijing Hanmi Pharm, Yangzhou Il-Yang Pharm, and GC China.
China subsidiaries of South Korea's listed pharmaceutical and biotech companies are undergoing massive changes.
Il-Yang Pharmaceutical and GC Biopharma have liquidated or sold their China subsidiaries within the past year. Hanmi Pharmaceutical (Hanmi Pharm)'s Beijing Hanmi Pharmaceutical, a local subsidiary of Hanmi Pharm in China, is affected by management disputes at headquarters. China subsidiaries of Chong Kun Dang, Kwang Dong Pharmaceutical, Huons, and Boryung have faced a sharp decline in sales and operations profits.
In contrast, more companies are establishing business operations in countries other than China. Celltrion, GC Biophama, Chong Kung Dang, SK Biopharmaceuticals
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)